A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients Publisher Pubmed



Soltani S^{1, 2} ; Zandi M^{1, 2} ; Shiri Aghbash P³ ; Rezaei M⁴ ; Mohammadzadeh N⁵ ; Afsharifar A⁶ ; Poortahmasebi V³
Source: Biotechnology and Applied Biochemistry Published:2022

Abstract

The necessity and impact of SARS-CoV2 on the world's health have led to developing and producing practical and useful vaccines for this deadly respiratory virus. Since April 2020, a vaccine for the virus has been developed. Given that comorbidities such as diabetes, hypertension, and cardiovascular disease are more prone to viruses and the risk of infection, vaccines should be designed to protect against high-risk respiratory illnesses. Including SARS, MERS, influenza, and the SARS-CoV-2 provide a safe immune response. Here, we review the information and studies that have been done to help develop strategies and perspectives for producing a safe and ideal vaccine to prevent COVID-19 in normal people, especially at high-risk groups such as diabetes patients. © 2020 International Union of Biochemistry and Molecular Biology, Inc.